Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation

详细信息    查看全文

• 作者：Samah Nassereddine¹ ; Taiga Nishihori² ; ⁴ ; Eric Padron³ ; ⁴ ; Rami Mahfouz⁵ ; Ali Bazarbachi⁶ ; Rami S. Komrokji³ ; ⁴ ; Mohamed A. Kharfan-Dabaja² ; ⁴ ; ^{Mohamed.Kharfan-Dabaja@Moffitt.org}
• 关键词：Hematopoietic cell allografting ; MDS ; Next generation sequencing ; Somatic mutation ; Survival
• 刊名：Clinical Lymphoma Myeloma and Leukemia
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：17
• 期：1
• 页码：7-13
• 全文大小：213 K
• 卷排序：17

文摘

Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic neoplastic disorders most commonly occurring in the elderly population; MDS has a tendency to progress to acute leukemia. Although epigenetic therapies have improved the outcomes of MDS patients, allogeneic hematopoietic cell transplantation remains the only curative option. Molecular characterization of MDS using next-generation sequencing has expanded not only the knowledge on MDS but also the depth of understanding of evolution and contribution of recurrent somatic mutations in precursor conditions. Rapidly evolving genomic information on MDS may provide clinicians with better risk stratification tools and may also aid in supplying useful information to allow comprehensive therapeutic decision making for MDS patients. In this concise review, we summarize the current knowledge and understanding of recurrent somatic mutations in MDS and discuss salient genomic information predicting response and influencing therapeutic outcomes in the context of allogeneic hematopoietic cell transplantation, as well as the potential application of these findings into future clinical practice.